cancer immunotherapy
COPD highlights BioInvent's potential in "Immunotherapy 2.0"
BioInvent recently announced promising clinical data for its lead cancer immunotherapy candidates, BI-1808 and BI-1206. To explain the results in more detail...
Alligator to maximize investment in immuno-oncology
Given ongoing discussions regarding partnerships for the Phase III study...
Alligator's CEO on current developments and the rights issue
Recent successes with mitazalimab in phase...
Ultimovac CEO: "Data can place us at the forefront of cancer vaccines"
Ultimovacs has announced positive survival data from the Phase II study...
Alligator Bioscience extends orphan drug status to Europe
Regulatory milestones continue to roll in for...
Phase II results indicate durability of response for Alligator's CD40 agonist
Alligator Bioscience has presented a second round of interim results...
Janssen's CAR T agreement supports Elicera's vision
Janssen and Cellular Biomedicine Group agreement worth 245...
Alligator prepares for new milestones with mitazalimab
The objective response rate of 52 percent measured with...
Alligator's CEO on the development status and the rights issue
Alligator Bioscience kicked off 2023 by presenting positive...
Ultimovacs updates timeline for INITIUM study
The phase II trial INITIUM with Ultimovac's universal cancer vaccine UV1...
Mendus to scale up clinical development in 2023
Mendus released its annual report for 2022 this week,...
FDA approves Alligator's Phase II study
Alligator BioScience continues to make progress with its...